Drug Database
DO

doxazosin (Cardura XL / doxazosin, GITS / Cardura CR)

✓ Approved

Ipsen Pharma · 小分子 · 小分子

什么是 doxazosin?

doxazosin 是一种小分子,由Ipsen Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Cardura XL, doxazosin, GITS, Cardura CR
公司Ipsen Pharma
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

doxazosin 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

相关研究文献

PubMedMedicine2026-11-13

When hypertensive crisis mimics septic shock: A case report of pheochromocytoma-induced severe lactic acidosis following GLP-1 receptor agonist administration.

Khan Areeba Ali AA, Aslam Saad S, Aqeel Mubarra M, Agha Muhammad Asim MA et al.

Pheochromocytoma is a rare catecholamine-secreting tumor that may present atypically with severe lactic acidosis and systemic inflammatory features, closely mimicking sepsis and delaying diagnosis. A possible interaction with glucagon-like peptide-1 (GLP-1) receptor agonists has been suggested but remains poorly understood. A 48-year-old woman with type 2 diabetes mellitus presented with acute nausea, vomiting, chills, severe abdominal pain, and hypertensive crisis within hours of self-administering tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist. She was febrile, tachycardic, and markedly hypertensive, with severe lactic acidosis and systemic inflammatory markers suggestive of sepsis. Initial evaluation favored sepsis; however, negative cultures, sustained severe hypertension, hyperlactatemia disproportionate to perfusion status, and elevated urinary normetanephrines redirected the evaluation toward an endocrine cause. The clinical and biochemical picture supported a diagnosis of probable pheochromocytoma. Imaging revealed a fat-containing left adrenal mass initially suggestive of myelolipoma, representing a diagnostic pitfall. The patient was managed with intravenous fluids, a continuous nicardipine infusion, and oral alpha-blockade with doxazosin. Empiric broad-spectrum antibiotics were started and later discontinued as infection became unlikely. Beta-blockade was withheld until adequate alpha-blockade was achieved. Supportive care and electrolyte correction were provided. Blood pressure and lactate improved over 48 hours with clinical stabilization. The patient was discharged on oral alpha-blockade with plans for outpatient functional imaging (64Cu-DOTATATE positron emission tomography) and definitive surgical evaluation. Pheochromocytoma should be considered in patients presenting with unexplained lactic acidosis and hypertensive crisis, even when sepsis appears likely. Catecholamine-driven type B lactic acidosis can closely mimic infectious shock. Fat-containing adrenal lesions do not exclude pheochromocytoma, and biopsy should be avoided. The temporal association with GLP-1 receptor agonist exposure is hypothesis-generating and warrants further investigation as use of these agents continues to expand.

PMID 43024315
阅读全文 →
PubMedJCEM case reports2026-11-12

Ruptured pheochromocytoma during preoperative doxazosin treatment.

AlMaimoni Reema R, AlFaraj Abdullah A, AlSaif Osama O, AlWosaibei Abdulaziz A et al.

Rupture of pheochromocytoma is rare but represents a life-threatening complication. A 43-year-old man with episodic hypertension, palpitations, and chest discomfort was incidentally found, during a computed tomography (CT) aortogram performed to rule out aortic dissection, to have a 5.2-cm right adrenal mass suspicious for pheochromocytoma. Biochemical testing confirmed catecholamine excess. He was started on oral doxazosin 1 mg daily, which was titrated to 2 mg daily after 1 week, followed by oral bisoprolol 2.5 mg daily in preparation for surgery. Five weeks later, he presented with severe right-sided abdominal pain and a blood pressure of 215/111 mmHg. Abdominal CT angiography showed interval enlargement of the adrenal mass with posterior rupture and a retroperitoneal hematoma without active bleeding. He was stabilized with conservative management and subsequently underwent robotic right adrenalectomy. Histopathology confirmed pheochromocytoma with necrosis, without angioinvasion or lymphatic invasion, and with negative margins. Pheochromocytoma rupture can occur despite appropriate α-blockade, and spontaneous hemorrhage remains the most likely proposed mechanism, although α-blockade may be a contributing factor in selected cases.

PMID 43017274
阅读全文 →
PubMedInternational journal of pharmaceutical compounding2026-10-31

Long-Term Stability of a Fixed-Dose Doxazosin and Finasteride Combination Formulation.

Mengesha Abebe A, Hess Jared J

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are commonly treated with a1-adrenoreceptor antagonists, 5a-reductase inhibitors, or a combination of both. The development of a fixed-dose doxazosin (DOX) and finasteride (FIN) formulation in a single dosage form is expected to improve efficacy, lower cost, and improve adherence to the treatment of male LUTS/BPH. The study aims to determine the stability of a fixed-dose combination formulation containing doxazosin (1 mg) and finasteride (5 mg). We conducted long-term stability studies of a fixed-dose DOX-FIN combination capsule. A stability-indicating HPLC method was developed and used to determine DOX and FIN in combination capsules simultaneously. DOX-FIN capsules were stored at 4°C, 25°C, and 40°C for 12 months. Samples were analyzed periodically using the HPLC method. The HPLC analysis showed that both DOX and FIN amounts remained above 90% of the initial values after 1 year when the capsules were stored at 4°C and 25°C. An elevated temperature (40°C) is not a recommended storage condition for the compounded capsules. Even at 40 °C, doxazosin stability remains above 90% up to 30 days, and finasteride remains above 90% up to 90 days. Long-term stability studies indicated that the combination of doxazosin and finasteride remained stable, with 90% of the drug still present in the formulation after one year for capsules stored at 4°C and 25°C.

PMID 42965423
阅读全文 →
PubMedPharmaceuticals (Basel, Switzerland)2026-10-27

Repurposing α-Blockers Alfuzosin and Doxazosin for Cancer Therapy: Integrated Experimental, Mechanistic, and Molecular Docking Studies.

Alanazi Mohammed M MM

Background/Objectives: Drug repurposing represents a promising strategy for determining new anticancer drugs through exploration of new therapeutic applications of clinically used drugs. Alfuzosin and doxazosin are α-adrenergic blockers clinically used for the treatment of benign prostatic hyperplasia (BPH). Growing evidence suggests that α-blockers may have anticancer properties. The purpose of this study was to investigate the potential of alfuzosin and doxazosin as repurposed anticancer medicines and to study their potential mechanisms of action, specifically their effects on apoptosis, cell cycle progression, enzyme panel, and cancer cell proliferation. Methods: The cytotoxicity of alfuzosin and doxazosin was investigated against multiple cancer cell lines using the MTT assay, with sunitinib used as a positive control. The enzyme inhibition effects of both drugs against potential target proteins were investigated, followed by cytometric analysis to determine the effects of the drugs on cell cycle progression and apoptosis in MCF-7 breast cancer cells. Molecular docking studies were also conducted to investigate possible interactions with the active site of EGFR. Results: Both alfuzosin and doxazosin demonstrated promising antiproliferative activity against cancer cells, with alfuzosin showing comparatively lower toxicity toward normal cells. The drugs also revealed potent inhibitory activity against the studied target proteins, pointing to their potential effect as multi-target inhibitors. Cell cycle analysis revealed that both drugs inhibited cell cycle progression at the G2/M phase in MCF-7 cells. Following treatment with alfuzosin and doxazosin, both drugs significantly induced apoptosis, with total apoptotic populations reaching 39.48% and 35.61%, respectively, compared with only 2.77% in untreated MCF-7 cells. Molecular docking studies further indicated the ability to interact with key amino acids within the EGFR active site. Conclusions: The present findings demonstrate the potential repurposing of alfuzosin and doxazosin as anticancer agents and offer a good background for further mechanistic and in vivo investigations.

PMID 42943216
阅读全文 →
PubMedSurgery2026-10-25

Preoperative normetanephrine levels, but not doxazosin dose, predict intraoperative hemodynamic instability in pheochromocytoma surgery.

Liljefors Victor V, Falhammar Henrik H, Stenman Adam A, Bränström Robert R et al.

Preoperative α-adrenergic blockade is routinely recommended before adrenalectomy for pheochromocytoma to reduce intraoperative hemodynamic instability. However, the need, intensity, and duration of preoperative blockade remain uncertain. This single-center, retrospective study included adult patients who underwent adrenalectomy for pheochromocytoma at Karolinska University Hospital between 2014 and 2023. The association between preoperative doxazosin treatment, plasma metanephrine and normetanephrine concentrations, and intraoperative hemodynamic instability was evaluated. Correlation analysis and multivariable linear regression were performed. Thirty-three patients were included (49% female; median age 59 years). Neither preoperative doxazosin dose nor treatment duration was associated with intraoperative systolic blood pressure reduction or intraoperative adenosine requirements. In contrast, higher preoperative metanephrine and normetanephrine concentrations were significantly associated with greater intraoperative vasoactive support requirements and a greater systolic blood pressure reduction after adrenal vein ligation. Tumor size showed a significant positive correlation with normetanephrine concentrations but was not independently associated with intraoperative hemodynamic instability. In multivariate analysis, preoperative normetanephrine concentration remained the only independent predictor of intraoperative reduction in systolic blood pressure after adrenal vein ligation. Preoperative normetanephrine concentration is associated with intraoperative hemodynamic instability in pheochromocytoma surgery, whereas doxazosin dose and treatment duration were not. These findings suggest that biochemical tumor activity may be more clinically relevant than the intensity of preoperative α-blockade when assessing perioperative cardiovascular risk.

PMID 42926151
阅读全文 →
PubMedEndocrine journal2026-10-18

Growth hormone-releasing hormone-secreting giant pheochromocytoma causing acromegaly: a case report with a review of the literature.

Kitamura Takuya T, Nanba Kazutaka K, Mishina Mutsuki M, Kanno Toru T et al.

The ectopic secretion of growth hormone (GH) or growth hormone-releasing hormone (GHRH) is responsible for fewer than 1% of acromegaly cases. Furthermore, within this small population, GHRH-secreting pheochromocytomas/paragangliomas (PPGLs) are even rarer. A 57-year-old Japanese woman presented to our hospital for treatment of a large left-sided pheochromocytoma (PCC). A physical examination revealed enlargement of the nose and lips as well as macroglossia, thereby raising the suspicion of acromegaly, which was biochemically confirmed by a 75-g oral glucose tolerance test. Magnetic resonance imaging demonstrated a slightly enlarged pituitary gland but no definitive tumor. A left adrenalectomy was performed after careful dose titration of doxazosin and metyrosine. Postoperative biochemical improvement of GH excess and immunohistochemical analysis of the resected tumor confirmed the diagnosis of GHRH-secreting PCC. Given the possibility that PPGLs produce various ectopic hormones and peptides, thorough physical examinations remain fundamental for the accurate diagnosis and optimal management of patients with these tumors.

PMID 42893849
阅读全文 →

注册免费账户还可查看另外 2286 篇文献

免费注册查看全部文献 →

了解更多doxazosin